enteroviru
import
human
pathogen
may
caus
sever
neurolog
complic
death
children
viru
caus
sever
outbreak
asiapacif
region
past
two
decad
consid
signific
public
health
problem
postpolioviru
erad
era
unlik
polioviru
effect
vaccin
approv
antivir
explor
agent
therefor
vital
import
sever
strategi
employ
develop
antivir
base
molecular
characterist
viru
among
small
molecul
develop
human
rhinovirus
polioviru
evalu
review
discuss
recent
develop
small
molecul
known
drug
resist
possibl
solut
anim
model
evalu
efficaci
antivir
although
investig
requir
clinic
applic
exist
candid
molecular
mechan
reveal
inhibit
replic
use
design
new
molecul
viru
futur
enteroviru
belong
genu
enteroviru
famili
picornavirida
sinc
viru
first
isol
california
number
outbreak
report
throughout
world
north
america
europ
australia
asia
past
two
decad
viru
serious
affect
asiapacif
area
becom
public
health
concern
sever
countri
within
area
commonli
caus
handfootandmouth
diseas
hfmd
children
consid
mild
syndrom
howev
young
children
infect
viru
develop
sever
neurolog
syndrom
asept
mening
enceph
poliomyelitislik
paralysi
even
death
exampl
outbreak
taiwan
result
case
sever
neurolog
complic
pulmonari
edema
hemorrhag
myocard
death
recent
larg
scale
outbreak
associ
hfmd
neurolog
symdrom
fatal
case
report
china
fatal
case
caus
infect
still
describ
asia
similar
human
enterovirus
polioviru
transmiss
occur
fecalor
rout
primari
replic
site
viru
presum
tonsil
intestin
lymphoid
tissu
therefor
viru
spread
gastrointestin
tract
infect
peopl
week
may
also
explain
isol
recov
throat
swab
stool
specimen
howev
clinic
featur
suggest
viru
reach
central
nervou
system
cn
peopl
suffer
infect
two
explan
spread
cn
viru
bloodstream
somehow
penetr
bloodbrain
barrier
viru
reach
cn
via
neuron
rout
recent
mous
studi
support
proposit
major
transmiss
rout
cn
may
retrograd
axon
transport
neuron
past
decad
effort
erad
polio
dramat
reduct
epidem
occur
effect
vaccin
improv
public
hygien
howev
emerg
infect
recent
develop
new
threat
children
especi
specif
treatment
vaccin
combat
ailment
support
therapi
still
primari
manag
sever
case
infect
symptomat
treatment
intraven
immunoglobulin
ivig
clinic
use
neutral
viru
nonspecif
suppress
inflamm
nevertheless
although
treatment
routin
appli
sever
case
infect
efficaci
requir
evalu
therefor
develop
specif
antivir
strategi
becom
urgent
issu
protect
children
hazard
infect
like
polioviru
prototyp
viru
famili
picornavirida
small
nonenvelop
viru
enclos
positivesens
singlestrand
rna
molecul
approxim
kilobas
initi
infect
viru
particl
attach
receptor
host
cell
releas
rna
genom
cytoplasm
two
host
protein
scaveng
receptor
human
pselectin
glycoprotein
identifi
cellular
receptor
genom
enter
host
cell
viral
rna
possess
intern
ribosom
entri
site
ire
poli
tail
serv
mrna
translat
capindepend
mechan
singl
larg
polyprotein
first
synthes
function
viral
protein
gener
matur
cleavag
mediat
viral
proteas
pro
pro
viral
rna
genom
mrna
viral
protein
translat
also
templat
replic
virusencod
rnadepend
rna
polymeras
rdrp
design
infect
cell
viral
rna
replic
occur
within
vesicular
membran
structur
cytoplasm
protein
viral
protein
highli
conserv
among
human
enterovirus
identifi
part
viral
replic
complex
within
vesicular
membran
thereaft
progeni
positivestrand
viral
rna
packag
viral
capsid
protein
form
new
infecti
virion
infect
eventu
initi
apoptot
pathway
pro
pro
protein
lyse
infect
cell
newli
produc
viral
particl
releas
lyse
cell
block
viru
entri
ideal
antivir
strategi
exampl
certain
extent
treat
sever
case
infect
ivig
partli
depend
nonspecif
neutral
viru
correspondingli
certain
anim
studi
shown
passiv
transfer
antiserum
immun
mice
could
provid
protect
challeng
accord
past
research
among
viral
capsid
protein
neutral
epitop
locat
protein
also
identifi
major
receptorbind
protein
infect
thu
develop
specif
antibodi
neutral
epitop
viral
capsid
protein
could
success
antivir
strategi
protein
polioviru
rhinoviru
also
shown
form
canyon
structur
import
receptor
bind
addit
conform
chang
protein
crucial
step
viral
particl
disassembl
releas
viral
rna
host
cell
therefor
design
small
molecul
target
may
interfer
infect
two
molecul
pleconaril
figur
pirodavir
found
suppress
rhinoviru
replic
target
capsid
protein
one
molecul
pleconaril
alreadi
appli
treat
lifethreaten
enteroviru
infect
verifi
specif
efficaci
pleconaril
mous
studi
perform
result
signific
improv
sever
symptom
infect
mice
howev
inhibit
capac
pleconaril
could
vari
differ
isol
viru
shia
et
al
report
pleconaril
nearli
ineffect
neutral
isol
outbreak
taiwan
use
skeleton
pleconaril
templat
computerassist
drug
design
develop
new
class
pyridyl
imidazolidinon
activ
among
pyridyl
imidazolidinon
one
compound
figur
demonstr
effect
replic
addit
small
molecul
lactoferrin
abund
ironbind
glycoprotein
colostrum
found
inhibit
bind
although
lactoferrin
approv
therapeut
purpos
could
consid
agent
prevent
viru
entri
matur
cleavag
critic
step
protein
synthesi
human
enterovirus
pro
pro
key
proteas
process
viral
precursor
polyprotein
rupintrivir
figur
origin
develop
inhibit
human
rhinoviru
infect
block
pro
activ
recent
year
compound
confirm
replic
inhibitor
blockag
pro
activ
addit
rupintrivir
compound
figur
shown
inhibit
human
rhinoviru
proteas
may
anoth
candid
treatment
suppress
pro
investig
antagon
pro
structurebas
design
could
highli
practic
especi
xray
crystal
structur
pro
recent
resolv
pro
cleav
viral
polyprotein
translat
factor
shut
hostcel
translat
also
consid
antivir
drug
target
inhibit
replic
unfortun
specif
inhibitor
develop
block
chymotrypsinrel
proteas
nevertheless
xray
crystal
structur
pro
relat
virus
human
rhinoviru
serotyp
coxsackieviru
disclos
enzymat
activ
pocket
proteas
similar
function
sequenc
catalyt
triad
pro
could
predict
combin
inform
structur
predict
catalyt
site
structurebas
inhibitor
design
still
applic
moreov
antivir
target
proteas
block
viral
protein
matur
may
also
assist
protect
host
protein
proteas
degrad
rna
genom
replic
rdrp
known
protein
target
polymeras
could
potent
strategi
specif
inhibit
replic
nucleosid
analogu
ribavirin
figur
studi
extens
picornaviru
polymeras
inhibitor
furthermor
nonnucleosid
analogu
piperazinecontain
pyrazolo
pyrimidin
deriv
figur
identifi
agent
select
resist
virus
shown
inhibit
viral
rna
replic
target
polymeras
addit
aurintricarboxyl
acid
origin
report
inhibitor
replicas
hcv
sarscov
also
exhibit
abil
inhibit
polymeras
mrna
cap
structur
translat
depend
ire
element
numer
studi
shown
iresdepend
translat
highli
control
iresspecif
transact
factor
itaf
addit
itaf
ire
far
upstream
element
bind
protein
report
neg
regul
ire
activ
compet
itaf
name
ptb
employ
protein
destruct
affect
ire
replic
suppress
concept
may
provid
new
strategi
develop
exampl
kaempferol
type
flavonoid
shown
inhibit
replic
ire
activ
chang
composit
itaf
enviroxim
found
antivir
compound
replic
rhinoviru
polioviru
analyz
enviroximeresist
mutant
target
site
enviroxim
identifi
viral
protein
viral
protein
precursor
play
key
role
format
enteroviru
replic
complex
develop
antivri
target
may
success
strategi
inhibit
replic
exampl
function
enviroximelik
compound
shown
novel
inhibitor
block
replic
vitro
rna
interfer
cellular
posttranscript
process
gene
express
silenc
sequencespecif
manner
base
concept
artifici
gener
small
interf
rna
sirna
wide
appli
studi
gene
function
sirna
effect
downregul
gene
express
viru
sequencespecif
sirna
consid
potenti
therapeut
agent
sever
studi
shown
virusspecif
sirna
success
suppress
replic
human
virus
polioviru
hcv
technolog
also
appli
experiment
treatment
infect
scientist
employ
suckl
mous
model
evalu
sirna
vivo
sirna
target
region
shown
potenti
therapeut
approach
innat
immun
host
natur
defens
system
viru
invas
product
type
interferon
ifn
initi
respons
innat
immun
result
activ
ifnstimul
gene
express
block
viral
replic
use
treat
hcv
infect
applic
enteroviru
infect
establish
evalu
whether
type
ifn
therapeut
effect
infect
recombin
murin
administ
newborn
mice
result
increas
surviv
rate
similar
vivo
studi
vitro
test
also
demonstr
potenc
reduc
replic
although
shown
proteas
could
degrad
interferon
regulatori
involv
type
ifn
downstream
signal
combin
pro
inhibitor
rupintrivir
treatment
consid
strategi
combat
ifn
signal
inhibit
vitro
studi
combin
treatment
show
synergist
effect
replic
accord
studi
type
ifn
could
consid
potent
treatment
nevertheless
recent
studi
demonstr
pro
could
ifn
antagonist
reduc
express
level
type
ifn
receptor
make
question
whether
type
ifn
activ
infect
rna
genom
synthes
rdrp
proofread
activ
faith
replic
viral
rna
mutat
newli
synthes
viral
genom
frequent
gener
replic
thu
variant
present
antivir
resist
phenotyp
could
often
select
antivir
treatment
exampl
elucid
mechan
action
base
appear
drugresist
mutant
whole
viral
genom
sequenc
address
drug
resist
practic
combin
treatment
learn
hiv
therapi
worth
evalu
ideal
molecul
select
combin
therapi
act
differ
mechan
base
two
recent
studi
evalu
combin
therapi
sever
combin
success
show
synergist
effect
inhibit
combin
rupintrivir
combin
rupintrivir
analogu
pirodavir
figur
therefor
combin
therapi
could
possibl
strategi
combat
verifi
effect
antivir
anim
studi
urgent
requir
addit
vitro
experi
sinc
chumakov
et
al
establish
experiment
anim
infect
model
neonat
mice
wide
use
vivo
studi
exampl
vivo
studi
conduct
use
icr
mice
evalu
protect
neutral
antibodi
investig
cn
involv
infect
howev
technic
difficulti
handl
pup
evalu
antivir
efficaci
toxic
addit
mouseadapt
strain
establish
serial
passag
mice
mouseadapt
viru
could
infect
icr
mice
oral
inocul
caus
lethal
cn
complic
tool
therefor
improv
vivo
pathogenesi
studi
mice
cynomolgu
monkey
use
studi
neuropathogen
howev
mous
model
mouseadapt
strain
may
rel
lowcost
effect
solut
evalu
new
antivir
base
experi
control
polioviru
epidem
vaccin
primari
strategi
prevent
infect
children
although
commerci
effect
vaccin
avail
sever
research
disclos
avail
vaccin
exampl
viral
capsid
protein
initi
design
immunogen
candid
subunit
vaccin
addit
subunit
vaccin
formaldehydeinactiv
wholeviru
also
wide
evalu
vaccin
candid
howev
sever
obstacl
need
overcom
vaccin
develop
first
lack
adult
mous
model
research
appli
passiv
immun
strategi
verifi
neutral
antibodi
gener
immun
dam
figur
overview
replic
molecular
mechan
potenti
inhibitor
bind
receptor
host
cell
releas
genom
rna
cytoplasm
neutral
antibodi
bind
receptorbind
capsid
protein
prevent
virusreceptor
interact
small
molecul
pleconaril
also
interfer
viru
entri
cytoplasm
viral
rna
target
virusspecif
sirna
suppress
viru
replic
singl
larg
polyprotein
first
synthes
cleav
viral
proteas
form
function
protein
rupintrivir
compound
inhibit
proteas
activ
prevent
matur
cleveag
protect
newborn
mice
overcom
limit
mous
model
mouseadapt
strain
mice
may
applic
vaccin
develop
sinc
mani
genotyp
isol
base
sequenc
select
refer
strain
could
anoth
obstacl
vaccin
product
therefor
urgent
establish
intern
collabor
share
virolog
epidemiolog
inform
nevertheless
phase
clinic
trial
human
conduct
evalu
safeti
immunogen
newli
develop
inactiv
vaccin
china
past
decad
erad
effort
substanti
reduc
number
poliomyel
case
worldwid
unfortun
reemerg
infect
becom
anoth
challeng
public
health
especi
asiapacif
region
unlik
poliomyel
effect
vaccin
still
avail
provid
immun
children
therefor
develop
agent
becom
urgent
issu
reliv
distress
epidem
area
base
replic
characterist
picornavirus
sever
strategi
develop
design
antivir
summar
figur
certain
antivir
origin
develop
human
rhinovirus
test
similar
viral
replic
mechan
experiment
mous
model
establish
candid
drug
evalu
assess
therapeut
efficaci
author
declar
compet
interest
author
contribut
rlk
wrote
manuscript
sr
particip
organ
coordin
help
draft
manuscript
author
read
approv
final
manuscript
